A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background & Aims Firmicutes bacteria produce metabolites that maintain the intestinal barrier and mucosal immunity. Firmicutes are reduced in the intestinal microbiota of patients with ulcerative colitis (UC). In a phase 1b trial of patients with UC, we evaluated the safety and efficacy of SER-287, an oral formulation of Firmicutes spores, and the effects of vancomycin preconditioning on expansion (engraftment) of SER-287 species in the colon. Methods We conducted a double-blind trial of SER-287 in 58 adults with active mild-to-moderate UC (modified Mayo scores 4–10, endoscopic subscores ≥1). Participants received 6 days of preconditioning with oral vancomycin (125 mg, 4 times daily) or placebo followed by 8 weeks of oral SER-287 or placebo. Patients were randomly assigned (2:3:3:3) to groups that received placebo followed by either placebo or SER-287 once weekly, or vancomycin followed by SER-287 once weekly, or SER-287 once daily. Clinical end points included safety and clinical remission (modified Mayo score ≤2; endoscopic subscores 0 or 1). Microbiome end points included SER-287 engraftment (dose species detected in stool after but not before SER-287 administration). Engraftment of SER-287 and changes in microbiome composition and associated metabolites were measured by analyses of stool specimens collected at baseline, after preconditioning, and during and 4 weeks after administration of SER-287 or placebo. Results Proportions of patients with adverse events did not differ significantly among groups. A higher proportion of patients in the vancomycin/SER-287 daily group (40%) achieved clinical remission at week 8 than patients in the placebo/placebo group (0%), placebo/SER-287 weekly group (13.3%), or vancomycin/SER-287 weekly group (17.7%) (P = .024 for vancomycin/SER-287 daily vs placebo/placebo). By day 7, higher numbers of SER-287 dose species were detected in stool samples from all SER-287 groups compared with the placebo group (P < .05), but this difference was not maintained beyond day 7 in the placebo/SER-287 weekly group. In the vancomycin groups, a greater number of dose species were detected in stool collected on day 10 and all subsequent time points through 4 weeks post dosing compared with the placebo group (P < .05). A higher number of SER-287 dose species were detected in stool samples on days 7 and 10 from subjects who received daily vs weekly SER-287 doses (P < .05). Changes in fecal microbiome composition and metabolites were associated with both vancomycin/SER-287 groups. Conclusions In this small phase 1b trial of limited duration, the safety and tolerability of SER-287 were similar to placebo. SER-287 after vancomycin was significantly more effective than placebo for induction of remission in patients with active mild to moderate UC. Engraftment of dose species was facilitated by vancomycin preconditioning and daily dosing of SER-287. ClinicalTrials.gov ID NCT02618187.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases
Lloyd-Price, J., Arze, C., Ananthakrishnan, A. N., Schirmer, M., Avila-Pacheco, J., Poon, T. W., Andrews, E., Ajami, N. J., Bonham, K. S., Brislawn, C. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1237-9 · Cited by 3,143
Self-citationDysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., Reyes, J. A., Shah, S. A., LeLeiko, N., Snapper, S. B., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-9-r79 · Cited by 2,713
Self-citationDethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
MetaPhlAn2 for enhanced metagenomic taxonomic profiling
Truong, D. T., Franzosa, E. A., Tickle, T. L., Scholz, M., Weingart, G., Pasolli, E., Tett, A., Huttenhower, C., & Segata, N. (2015) · Nature Methods · doi:10.1038/nmeth.3589 · Cited by 2,185
Self-citationGut microbiome structure and metabolic activity in inflammatory bowel disease
Franzosa, E. A., Sirota-Madi, A., Avila-Pacheco, J., Fornelos, N., Haiser, H. J., Reinker, S., Vatanen, T., Hall, A. B., Mallick, H., McIver, L. J., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0306-4 · Cited by 1,995
Self-citationThe Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789 · cited 3×
“Spore-forming Firmicutes, particularly the families Clostridiaceae, Lachnospiraceae, and Ruminococcaceae, have an important role in gut homeostasis through production of metabolites, which enhance gastrointestinal barrier and mucosal immune functions.(4) Although the pathogenesis of disease remains unclear, changes in…”
BackgroundMethodInfluentialMicrobial co-occurrence relationships in the human microbiome
Faust, K., Sathirapongsasuti, J. F., Izard, J., Segata, N., Gevers, D., Raes, J., & Huttenhower, C. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002606 · Cited by 1,527
Self-citationMoayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276 · cited 2×
“Importantly, the microbial taxa associated with clinical remission included spore-forming Firmicutes, such as Lachnospiraceae, Ruminococcaceae, and Eubacteriaceae.8,13,15 The potential role of the microbiome in UC pathogenesis, coupled with FMT efficacy data, motivated our development of SER-287 as a novel therapeutic.”
BackgroundStrains, functions and dynamics in the expanded Human Microbiome Project
Lloyd-Price, J., Mahurkar, A., Rahnavard, G., Crabtree, J., Orvis, J., Hall, A. B., Brady, A., Creasy, H. H., McCracken, C., Giglio, M. G., et al. (2017) · Nature · doi:10.1038/nature23889 · Cited by 1,267 · cited 2×
“In the placebo/ placebo arm, microbiome changes are due to natural fluctuations.(19) Compared with placebo/placebo, minimal compositional shifts were observed in the placebo/SER-287 weekly arm consistent with low magnitude engraftment.”
MethodSelf-citationDynamics of the human gut microbiome in inflammatory bowel disease
Halfvarson, J., Brislawn, C. J., Lamendella, R., Vázquez-Baeza, Y., Walters, W. A., Bramer, L. M., D'Amato, M., Bonfiglio, F., McDonald, D., Gonzalez, A., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.4 · Cited by 1,204 · cited 1×
“Temporal shifts in microbial composition and their metabolites have been postulated to precipitate disease flares.(6,10,11) Modulating the microbiome and the microbial triggers of inflammation and immune activation may provide an improved therapeutic option with limited off-target effects.”
BackgroundSartor, R. B., & Wu, G. D. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.012 · Cited by 808
Garrett, W. S., Gallini, C. A., Yatsunenko, T., Michaud, M., DuBois, A., Delaney, M. L., Punit, S., Karlsson, M., Bry, L., Glickman, J. N., et al. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.08.004 · Cited by 788
Commensal clostridia: Leading players in the maintenance of gut homeostasis
Lopetuso, L. R., Scaldaferri, F., Petito, V., & Gasbarrini, A. (2013) · Gut Pathogens · doi:10.1186/1757-4749-5-23 · Cited by 753
Clostridium difficile and the microbiota
Seekatz, A. M., & Young, V. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72336 · Cited by 255
HIV persists throughout deep tissues with repopulation from multiple anatomical sources
Chaillon, A., Gianella, S., Dellicour, S., Rawlings, S. A., Schlub, T. E., De Oliveira, M. F., Ignacio, C., Porrachia, M., Vrancken, B., & Smith, D. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134815 · Cited by 250
Human colon mucosal biofilms from healthy or colon cancer hosts are carcinogenic
Tomkovich, S., Dejea, C. M., Winglee, K., Drewes, J. L., Chung, L., Housseau, F., Pope, J. L., Gauthier, J., Sun, X., Mühlbauer, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124196 · Cited by 209 · cited 1×
“In addition, FMT carries risk of transmission of proinflammatory strains and potentially carcinogenic bacteria.(9,43) In contrast, SER-287 is a multifunctional consortia of bacterial spores purified under stringent manufacturing processes.”
BackgroundKump, P., Wurm, P., Gröchenig, H. P., Wenzl, H., Petritsch, W., Halwachs, B., Wagner, M., Stadlbauer, V., Eherer, A., Hoffmann, K. M., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14387 · Cited by 196
Cited by
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. L., Diao, L., Bryant, J. A., Sims, M., Kraft, C. S., Cohen, S. H., Berenson, C. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2106516 · Cited by 558
Self-citationUlcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
Wangchuk, P., Yeshi, K., & Loukas, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.08.003 · Cited by 333
Key determinants of success in fecal microbiota transplantation: From microbiome to clinic
Porcari, S., Benech, N., Valles-Colomer, M., Segata, N., Gasbarrini, A., Cammarota, G., Sokol, H., & Ianiro, G. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.03.020 · Cited by 331
Huang, Z., Li, Y., Park, H., Ho, M., Bhardwaj, K., Sugimura, N., Lee, H. W., Meng, H., Ebert, M. P., Chao, K., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2237645 · Cited by 41
Metadata
- Authors
- Henn, M. R., O’Brien, E. J., Diao, L., Feagan, B. G., Sandborn, W. J., Huttenhower, C., Wortman, J. R., McGovern, B. H., Wang-Weigand, S., Lichter, D. I., Chafee, M., Ford, C. B., Bernardo, P., Zhao, P., Simmons, S., Tomlinson, A. D., Cook, D. N., Pomerantz, R. J., Misra, B. K., Auninš, J. G., & Trucksis, M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 160
- Issue
- 1
- Pages
- 115-127.e30
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W3047307029
- Cited by
- 118
- References
- 18
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.